Introduction: Transforming Liquid Biopsy
Non-Small Cell Lung Cancer (NSCLC) accounts for over 85% of lung cancer cases globally and remains one of the leading causes of cancer-related deaths. Early detection and longitudinal monitoring are critical, yet traditional tissue biopsies are invasive, costly, and limited in representing tumor heterogeneity.
Circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs) have emerged as powerful biomarkers for real-time tumor profiling, treatment monitoring, and predicting metastasis risk. GBC’s CellBio™ a2000 platform addresses these needs by providing automated, size-based, label-free isolation of CTCs and CTMs — unlocking a new paradigm for precision oncology.
Study Overview: NSCLC Clinical Validation
In a prospective study involving 35 NSCLC patients, the CellBio™ a2000 system demonstrated its ability to reliably capture intact CTCs and CTMs from 7.5 ml of blood using patented iFiltration™ technology.
Key highlights:
• Dual Staining Strategy:
• Papanicolaou stain → detailed morphological structure
• Immunofluorescence staining → molecular characterization
Combining both approaches improved detection sensitivity and accuracy.
• Detection Performance:
• 74% overall sensitivity for CTCs/CTMs in NSCLC
• 100% detection in untreated patients, enabling potential early-stage diagnosis
• 68% detection in patients undergoing therapy, supporting real-time monitoring
• CTMs in 7 Patients: Indicates high metastatic potential and enables risk stratification.
Why It Matters for Pharma
Pharmaceutical companies developing targeted therapies and immuno-oncology treatments are increasingly seeking liquid biopsy solutions for:
• Patient Stratification — Identify responders and non-responders earlier
• Treatment Monitoring — Track therapy effectiveness dynamically
• Minimal Residual Disease (MRD) Detection — Enable adaptive treatment strategies
• Biomarker Discovery — Access intact, viable cells for downstream multi-omics analysis
CellBio™ a2000 offers a robust, validated platform to facilitate clinical trials and companion diagnostics.
Future Directions
By integrating AI-assisted image analysis and multi-omic profiling pipelines, GBC is paving the way for next-generation personalized oncology solutions. Our collaborations with leading academic centers and biotech innovators further strengthen our ability to deliver clinically actionable insights.
Call-to-Action
Partner with GBC to harness the power of CellBio™ a2000 and drive breakthroughs in precision oncology.
Contact us → https://www.gbc.com.tw/en/contactus
Non-Small Cell Lung Cancer (NSCLC) accounts for over 85% of lung cancer cases globally and remains one of the leading causes of cancer-related deaths. Early detection and longitudinal monitoring are critical, yet traditional tissue biopsies are invasive, costly, and limited in representing tumor heterogeneity.
Circulating tumor cells (CTCs) and circulating tumor microemboli (CTMs) have emerged as powerful biomarkers for real-time tumor profiling, treatment monitoring, and predicting metastasis risk. GBC’s CellBio™ a2000 platform addresses these needs by providing automated, size-based, label-free isolation of CTCs and CTMs — unlocking a new paradigm for precision oncology.
Study Overview: NSCLC Clinical Validation
In a prospective study involving 35 NSCLC patients, the CellBio™ a2000 system demonstrated its ability to reliably capture intact CTCs and CTMs from 7.5 ml of blood using patented iFiltration™ technology.
Key highlights:
• Dual Staining Strategy:
• Papanicolaou stain → detailed morphological structure
• Immunofluorescence staining → molecular characterization
Combining both approaches improved detection sensitivity and accuracy.
• Detection Performance:
• 74% overall sensitivity for CTCs/CTMs in NSCLC
• 100% detection in untreated patients, enabling potential early-stage diagnosis
• 68% detection in patients undergoing therapy, supporting real-time monitoring
• CTMs in 7 Patients: Indicates high metastatic potential and enables risk stratification.
Why It Matters for Pharma
Pharmaceutical companies developing targeted therapies and immuno-oncology treatments are increasingly seeking liquid biopsy solutions for:
• Patient Stratification — Identify responders and non-responders earlier
• Treatment Monitoring — Track therapy effectiveness dynamically
• Minimal Residual Disease (MRD) Detection — Enable adaptive treatment strategies
• Biomarker Discovery — Access intact, viable cells for downstream multi-omics analysis
CellBio™ a2000 offers a robust, validated platform to facilitate clinical trials and companion diagnostics.
Future Directions
By integrating AI-assisted image analysis and multi-omic profiling pipelines, GBC is paving the way for next-generation personalized oncology solutions. Our collaborations with leading academic centers and biotech innovators further strengthen our ability to deliver clinically actionable insights.
Call-to-Action
Partner with GBC to harness the power of CellBio™ a2000 and drive breakthroughs in precision oncology.
Contact us → https://www.gbc.com.tw/en/contactus
){kind=link}